---
document_datetime: 2026-01-28 15:55:57
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/erbitux-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: erbitux-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6665594
conversion_datetime: 2026-01-29 12:32:42.033357
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Erbitux

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | A. ADMINISTRATIVE CHANGES - A.7 | 28/01/2026                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323569                     | Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                                                                                                                                                                                  |            | PL              |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|
| Variation type II / EMA/VR/0000291784 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.z Other changes - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.3 Including batch control/testing for a biological/immunological product and any of the test methods performed at that site is a biological / immunological / immunochemical method - Accepted B.II.e.1.a Qualitative and quantitative composition - B.II.e.1.a.3 Sterile medicinal products and biological/ immunological medicinal products - Accepted | 04/12/2025 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000314715   | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                    | 28/11/2025   | N/A   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type IB / EMA/VR/0000294109   | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                         | 19/09/2025   | N/A   |
| Variation type IB / EMA/VR/0000273782   | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.f The scale for a biological/immunological medicinal product is increased / decreased without process change (e.g. duplication of line) - Accepted | 16/06/2025   | N/A   |